Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
NCT ID: NCT04725188
Last Updated: 2025-08-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
255 participants
INTERVENTIONAL
2021-04-20
2024-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
NCT05226598
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
NCT04738487
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
NCT02864394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 via IV infusion Q3W. Each cycle will be 21 days.
Pembrolizumab/Vibostolimab coformulation
Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Docetaxel
Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Arm 2: Pembrolizumab/Vibostolimab coformulation
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle will be 21 days.
Pembrolizumab/Vibostolimab coformulation
Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Arm 3: Placebo + Docetaxel
Participants receive normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 IV infusion Q3W. Each cycle will be 21 days.
Docetaxel
Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Placebo
Normal saline IV infusion Q3W up to approximately 2 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab/Vibostolimab coformulation
Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Docetaxel
Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Placebo
Normal saline IV infusion Q3W up to approximately 2 years
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or reactive oxygen species (ROS) 1 directed therapy is not indicated as primary therapy
* Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies
* Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
* Has PD as determined by the investigator after platinum doublet chemotherapy for metastatic disease
* Has measurable disease defined as at least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
* Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
* Has a life expectancy of at least 3 months
* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days prior to randomization
* Male participants randomized to docetaxel are eligible to participant if they agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) must agree to follow contraceptive guidance as per study protocol unless confirmed to be azoospermic during the intervention period and for at least 180 days after the last dose of docetaxel
* Female participants must be not pregnant, not breastfeeding, and not be a woman of child-bearing potential (WOCBP). A WOCBP is eligible is she agrees to either use contraception, or be abstinent from heterosexual intercourse during the intervention period and for ≥120 days after the last dose of study intervention. If a WOCBP is randomized to docetaxel, she agrees not to donate eggs and either uses contraception or be abstinent from heterosexual intercourse during the treatment period and for ≥180 days after the last dose of docetaxel
* Has adequate organ function
Exclusion Criteria
* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy
* Has received docetaxel as monotherapy or in combination with other therapies
* Has received previous treatment with another agent targeting the T-cell immunoreceptor with immunoglobulin \[Ig\] and immunoreceptor tyrosine-based inhibitory motif \[ITIM\] domains (TIGIT) pathway
* Has received radiotherapy within 2 weeks of start of study intervention. One week washout is permitted for palliative radiation to non-CNS disease
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
* Has severe hypersensitivity (≥Grade 3) to docetaxel or pembrolizumab/vibostolimab coformulation and/or any of its excipients
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention
* Has interstitial lung disease, or history of pneumonitis requiring steroids for treatment
* Has known history of active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
* Has had an allogenic tissue/solid organ transplant
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Medical Center ( Site 2522)
Los Angeles, California, United States
Illinois Cancer Care ( Site 2534)
Peoria, Illinois, United States
Baptist Health Lexington-Research ( Site 2502)
Lexington, Kentucky, United States
University of Maryland ( Site 2528)
Baltimore, Maryland, United States
Hattiesburg Clinic Hematology/Oncology ( Site 2511)
Hattiesburg, Mississippi, United States
Mercy Research - Cancer and Hematology Center ( Site 2535)
Springfield, Missouri, United States
Mercy Research - David C. Pratt Cancer Center ( Site 2532)
St Louis, Missouri, United States
Montefiore- Einstein Center for Cancer Care-Oncology ( Site 2509)
The Bronx, New York, United States
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 2526)
Cincinnati, Ohio, United States
St Francis Cancer Center-Research Office ( Site 2531)
Greenville, South Carolina, United States
Centro de Oncología e Investigación de Buenos Aires ( Site 0008)
Berazategui, Buenos Aires, Argentina
Hospital Privado de Comunidad ( Site 0004)
Mar del Plata, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0002)
Mar del Plata, Buenos Aires, Argentina
Instituto de Oncología de Rosario ( Site 0003)
Rosario, Santa Fe Province, Argentina
Hospital Privado Universitario de Córdoba ( Site 0001)
Córdoba, , Argentina
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0005)
La Rioja, , Argentina
Canberra Hospital ( Site 0104)
Canberra, Australian Capital Territory, Australia
Gold Coast University Hospital-Clinical Trials Service ( Site 0106)
Southport, Queensland, Australia
Fiona Stanley Hospital-Medical Oncology ( Site 0102)
Murdoch, Western Australia, Australia
Medizinische Universität Graz ( Site 0201)
Graz, Styria, Austria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0203)
Linz, Upper Austria, Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0204)
Vienna, , Austria
AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0333)
Mechelen, Antwerpen, Belgium
UZ Brussel ( Site 0336)
Brussels, Bruxelles-Capitale, Region de, Belgium
Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0337)
Charleroi, Hainaut, Belgium
Jessa Ziekenhuis-Pulmonology & Thoracic Oncology ( Site 0338)
Hasselt, Limburg, Belgium
AZ Nikolaas ( Site 0334)
Sint-Niklaas, Oost-Vlaanderen, Belgium
Hospital Nossa Senhora da Conceição ( Site 0403)
Porto Alegre, Rio Grande do Sul, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 0400)
São Paulo, São Paulo, Brazil
Centro de Tratamento de Tumores Botafogo - CTTB-Pesquisa Clínica ( Site 0402)
Rio de Janeiro, , Brazil
Hospital Paulistano ( Site 0406)
São Paulo, , Brazil
Rigshospitalet ( Site 0702)
Copenhagen, Capital Region, Denmark
Odense Universitetshospital ( Site 0700)
Odense, Region Syddanmark, Denmark
Sygehus Soenderjylland-Kraeftambulatoriet ( Site 0705)
Sønderborg, Region Syddanmark, Denmark
Oulun yliopistollinen sairaala ( Site 0902)
Oulu, North Ostrobothnia, Finland
Tampereen yliopistollinen sairaala-Oncology ( Site 0906)
Tampere, Pirkanmaa, Finland
Vaasan Keskussairaala ( Site 0903)
Vaasa, Pohjanmaa, Finland
Turku University Hospital-The Department of Pulmonary Medicine ( Site 0905)
Turku, Southwest Finland, Finland
Nouvel Hôpital Civil (NHC) ( Site 1000)
Strasbourg, Alsace, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1009)
Bordeaux, Aquitaine, France
Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre ( Site 1006)
Caen, Calvados, France
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1008)
Toulouse, Haute-Garonne, France
Clinique Ambroise Paré ( Site 1007)
Beuvry, Pas-de-Calais, France
Centre Hospitalier du Mans ( Site 1002)
Le Mans, Sarthe, France
Gustave Roussy ( Site 1005)
Villejuif, Val-de-Marne, France
HIA Sainte Anne ( Site 1003)
Toulon, Var, France
Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1004)
Avignon, Vaucluse, France
Onkologie Ravensburg ( Site 1104)
Ravensburg, Baden-Wurttemberg, Germany
Klinikverbund Allgaeu gGmbH ( Site 1109)
Immenstadt im Allgäu, Bavaria, Germany
Helios Dr. Horst Schmidt Kliniken ( Site 1108)
Wiesbaden, Hesse, Germany
Universitätsklinikum Bonn ( Site 1111)
Bonn, North Rhine-Westphalia, Germany
Helios Klinikum Emil von Behring Berlin-Zehlendorf ( Site 1106)
Berlin, , Germany
Soroka Medical Center ( Site 1202)
Beersheba, , Israel
Rambam Health Care Campus-Oncology ( Site 1203)
Haifa, , Israel
Shaare Zedek Medical Center-Oncology ( Site 1206)
Jerusalem, , Israel
Sourasky Medical Center ( Site 1205)
Tel Aviv, , Israel
Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1307)
Rome, Lazio, Italy
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)
Naples, Napoli, Italy
CRO-IRCCS-medical oncology ( Site 1304)
Aviano, Pordenone, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga-Oncologia Polmonare ( Site 1300)
Orbassano, Torino, Italy
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1306)
Florence, Tuscany, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 1305)
Milan, , Italy
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1301)
Milan, , Italy
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1303)
Roma, , Italy
Hospital Sultan Ismail ( Site 1503)
Johor Bahru, Johor, Malaysia
University Malaya Medical Centre ( Site 1501)
Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan ( Site 1500)
Kuantan, Pahang, Malaysia
Beacon Hospital Sdn Bhd ( Site 1504)
Petaling Jaya, Selangor, Malaysia
Przychodnia Lekarska KOMED ( Site 1704)
Konin, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warsaw, Masovian Voivodeship, Poland
Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (
Saint Petersburg, Leningradskaya Oblast', Russia
Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 1911)
Saint Petersburg, Leningradskaya Oblast', Russia
Moscow Clinical Research Center-Chemotherapy department ( Site 1910)
Moscow, Moscow, Russia
Central Clinical Hospital of the Presidential Administrative Department ( Site 1902)
Moscow, Moscow, Russia
Hadassah Medical-Oncology department ( Site 1912)
Moscow, Moscow Oblast, Russia
Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 1909)
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary ( Site 1908)
Omsk, Omsk Oblast, Russia
GBUZ LOKB-Oncology department #1 ( Site 1905)
Saint Petersburg, Sankt-Peterburg, Russia
N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S
Saint Petersburg, Sankt-Peterburg, Russia
Seoul National University Bundang Hospital ( Site 2003)
Seongnam, Kyonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2005)
Suwon, Kyonggi-do, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 2004)
Cheongju-si, North Chungcheong, South Korea
Asan Medical Center-Oncology ( Site 2000)
Songpagu, Seoul, South Korea
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 2102)
Barcelona, Catalonia, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2101)
Madrid, , Spain
Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 2103)
Seville, , Spain
Ospedale Regionale Bellinzona e Valli ( Site 2203)
Bellinzona, Canton Ticino, Switzerland
Chang Gung Memorial Hospital at Kaohsiung ( Site 2303)
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Taichung Veterans General Hospital-Chest ( Site 2307)
Taichung, , Taiwan
NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 2302)
Tainan City, , Taiwan
National Taiwan University Hospital-Oncology ( Site 2304)
Taipei, , Taiwan
Mackay Memorial Hospital-Chest Medicine ( Site 2305)
Taipei, , Taiwan
Chulalongkorn University ( Site 2403)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 2400)
Bangkok, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7684A-002
Identifier Type: OTHER
Identifier Source: secondary_id
KEYVIBE-002
Identifier Type: OTHER
Identifier Source: secondary_id
2022-501252-28-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1275-8661
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-004034-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
7684A-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.